Healthcare Industry News: Positron Corporation
News Release - April 30, 2009
Positron Joint Venture Receives FDA Approval for Attrius(TM) Scanner Product LineINDIANAPOLIS--(HSMN NewsFeed)--Positron Corporation (OTCBB:POSC )(the “Company”), a cardiac molecular imaging solutions company, announced today that the United States Food and Drug Administration (FDA) has approved Neusoft Positron Medical Systems 510(k) submission for its Attrius(TM) Positron Emission Tomography (PET) scanner product line developed by the Company and its joint venture with Neusoft Medical Systems based in Shenyang, China. Positron’s Attrius(TM) product line was developed to provide physicians a state of the art cardiac PET molecular imaging system. The AttriusTM scanner comes complete with a feature set designed specifically for cardiac perfusion imaging such as a coronary artery disease software suite that includes; mercator projections, normal database comparison, coronary artery tree and distribution overlay map, rapid segmented attenuation correction, motion correction, and open acquisition architecture for today’s challenging quantitative flow reserve imaging.
Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Radiopharmaceutical Products and Molecular Imaging Devices. The Pharmaceutical Products segment offers world’s first robotic systems (Nuclear Pharm-Assist(R) & Cardio-Assist(TM)) for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases; the Molecular Imaging Devices segment provides PET scanners (Attrius(TM)) and SPECT cameras (Pulse(R));. Positron’s SPECT and PET cardiac molecular imaging systems and radiopharmaceutical deliver devices are installed in more than 150 hospitals and physician offices around the world. Additional information may be found at http://www.positron.com.
Forward Looking Statements:
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
For further information please contact Positron Corporation at (866)-613-7587
Source: Positron Corporation
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.